• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Steven Peskin Gives a Sneak Peek of His Session on Value-Based Contracting

Video

Horizon Blue Cross Blue Shield of New Jersey has been involved in a number of value-based cancer care initiatives that will be highlighted during an upcoming Asembia session, said Steven Peskin, MD, MBA, executive director, director of population health, Horizon Blue Cross Blue Shield of New Jersey.

Horizon Blue Cross Blue Shield of New Jersey has been involved in a number of value-based cancer care initiatives that will be highlighted during an upcoming Asembia session, said Steven Peskin, MD, MBA, executive director, director of population health, Horizon Blue Cross Blue Shield of New Jersey.

Transcript

Can you provide a sneak peek of some of your key talking points at Asembia?

I'll be talking about things that we've been doing and value-based cancer care, and certainly that covers a fairly broad expanse. We've been involved with a number of our oncology clinical partners at Horizon Blue Cross Blue Shield of New Jersey, with shared savings and moving into shared risk. We worked in non–small cell lung cancer, breast cancer, prostate, non-Hodgkin’s lymphoma, colorectal, among others. And so that's what I'll be highlighting.

We also had an oncology medical home model, which was partly benchmarked from Dr. [Barbara] McAneny’s work and Dr. [John] Sprandio’s work and had some elements of the OCM [Oncology Care Model]—we did not formally participate in the OCM, and we’re, as a company, in the very early stages and some of the preliminary discussions around Capitol Hill on the OCM. But we elected to go our own way with our own value payment models and oncology medical home.

Related Videos
Debra Boyer, MD, MHPE, ATSF.
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Plasminogen is vital in the body's coagulation process and breaking down clots | image credit: peterschreiber.media - stock.adobe.com
ISPOR 2024 Recap
Chris Pagnani, MD, PC
Screenshot of Stephen Freedland, MD, during a video interview
Phaedra Corso, PhD, associate vice president for research at Indiana University
Julie Patterson, PharmD, PhD
William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Michael Morse, MD, Duke Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.